CRSP — Crispr Therapeutics AG Income Statement
0.000.00%
Last trade - 00:00
- $4.67bn
- $2.98bn
- $371.21m
- 47
- 23
- 90
- 53
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 290 | 0.719 | 915 | 1.2 | 371 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 243 | 355 | 541 | 674 | 594 |
Operating Profit | 46.7 | -354 | 374 | -673 | -223 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 67.3 | -348 | 380 | -651 | -151 |
Provision for Income Taxes | |||||
Net Income After Taxes | 66.9 | -349 | 378 | -650 | -154 |
Net Income Before Extraordinary Items | |||||
Net Income | 66.9 | -349 | 378 | -650 | -154 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 66.9 | -349 | 378 | -650 | -154 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.17 | -5.29 | 4.7 | -8.36 | -1.94 |